drugset
drugset / Trial / NCT05200273

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114

NCT05200273 ↗

Phase 1 Unknown 30 enrolled Akeso
NaSingle-groupOpen-labelTreatment

Summary

A Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK114.

Timeline

Start
2022-03-15
Primary completion
2023-12-30
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject AK114 Unknown — Subcutaneous

Indications

cancer metastatic neoplasm